C4 Therapeutics Inc (CCCC) Stock Price, Quote & News

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 231 0700

Website: www.c4therapeutics.com

Address:

490 Arsenal Way, Suite120, Watertown, United States

zawojak Jul. 24 at 6:18 AM

$CCCC my bios actually nog doing bad in this bear market. I have biggest loss with military stocks :/

0 · Reply

Andysss Jul. 23 at 1:12 PM

$CCCC well said. We are in for toxic combo. 10y flashing red. @LabPsycho are still holding ?

1 · Reply

JuggernautRaider Jul. 23 at 1:32 AM

$MIST thinking of loading up like I did $NUVB and $IMRX and $CCCC at $1.50 🧐

0 · Reply

JuggernautRaider Jul. 22 at 4:12 PM

$TNXP buying opportunities 😋 $IMRX $CCCC $PFE all on my Uncle Dave’s shopping list 📕 😋 💊

0 · Reply

JuggernautRaider Jul. 21 at 8:39 PM

Eat me like a sweet Italian sausage you Jabbroni. Stop whining - I don’t speak Why-Knees. Do your own due diligence or be quiet you baby $NUVB $CCCC $IMRX and $SLS all winners 🏆 🏆 🏆 🏆

1 · Reply

Jh900 Jul. 21 at 3:43 PM

$CCCC not really stressed about pullbacks , although at 5.20 I was in 2k profit I should have taken profit you can’t predict these types of dips (the dips that keep dipping ) and be greatful of a good buying opportunity here . I want at least 10 by next year

0 · Reply

JuggernautRaider Jul. 21 at 10:15 AM

$CCCC this is a 4 diamond stock 💎 👊 what is the one thing it is missing? 👍

0 · Reply

JuggernautRaider Jul. 20 at 7:00 PM

$MAT gonna be a buyer 😋 soon. $TNXP $IMRX $CCCC … soon

0 · Reply

zawojak Jul. 20 at 3:46 PM

$CCCC Looks like no buyers for small cap stocks 😬 currently .

1 · Reply

buylocellhi Jul. 20 at 3:23 PM

$CCCC this is the 3rd time we have touched the $3.40-3.50 price point. Let’s hope this is the 3rd and last time so we can start moving up 📈

0 · Reply

C4 Therapeutics Transcript: AGM 2026

Jun 18, 2026, 9:00 AM EDT - 5 weeks ago

C4 Therapeutics Transcript: KOL event

Jun 18, 2026, 9:00 AM EDT - 5 weeks ago

C4 Therapeutics Slides: KOL event

2026-06-11T12:00:29.000Z - 6 weeks ago

C4 Therapeutics presents further analysis from cemsidomide trial

$C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population$

Jun 11, 2026, 7:00 AM EDT - 6 weeks ago

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

Jun 11, 2026, 7:00 AM EDT - 6 weeks ago

C4 Therapeutics Slides: Corporate presentation

Jun 4, 2026, 9:20 AM EDT - 7 weeks ago

C4 Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-05-29T15:51:38.000Z - 2 months ago

C4 Therapeutics jumps after Bristol Myers myeloma data

BMY

May 26, 2026, 2:30 PM EDT - 2 months ago

C4 Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026, 7:00 AM EDT - 2 months ago

C4 Therapeutics to Participate in Upcoming Conferences

May 18, 2026, 4:01 PM EDT - 2 months ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-05-12T12:40:38.000Z - 2 months ago

C4 Therapeutics reports Q1 EPS (20c), consensus (26c)

May 12, 2026, 7:00 AM EDT - 2 months ago

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 12, 2026, 7:00 AM EDT - 2 months ago

C4 Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

C4 Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

C4 Therapeutics Slides: Investor presentation

Apr 29, 2026, 8:00 AM EDT - 3 months ago

C4 Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

C4 Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 9:34 AM EDT - 3 months ago

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

2026-04-09T11:07:07.000Z - 3 months ago

C4 Therapeutics expands long-term partnership with Roche

Apr 9, 2026, 6:59 AM EDT - 3 months ago

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Apr 8, 2026, 7:00 AM EDT - 3 months ago

C4 Therapeutics Slides: Corporate presentation

2026-03-25T11:25:28.000Z - 4 months ago

C4 Therapeutics doses first patient in cemsidomide trial

$C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma$

Mar 25, 2026, 7:00 AM EDT - 4 months ago

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

Mar 10, 2026, 8:00 AM EDT - 4 months ago

C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 3, 2026, 11:50 AM EST - 5 months ago

C4 Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 6:00 AM EST - 5 months ago

C4 Therapeutics Slides: Corporate presentation

2026-02-27T10:25:32.000Z - 5 months ago

C4 Therapeutics price target raised to $7 from $5 at Barclays

2026-02-26T12:08:51.000Z - 5 months ago

C4 Therapeutics reports Q4 EPS (18c), consensus (34c)

Feb 26, 2026, 7:00 AM EST - 5 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 26, 2026, 7:00 AM EST - 5 months ago

C4 Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 5 months ago

C4 Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 7:00 AM EST - 5 months ago

C4 Therapeutics Slides: Corporate presentation

2026-02-23T17:07:13.000Z - 5 months ago

C4 Therapeutics price target raised to $30 from $20 at Brookline

Feb 23, 2026, 7:10 AM EST - 5 months ago

C4 Therapeutics to Participate in Upcoming March Conferences

2026-02-23T12:06:05.000Z - 5 months ago

C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial

$C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma$

Feb 23, 2026, 7:00 AM EST - 5 months ago

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Feb 11, 2026, 11:30 AM EST - 5 months ago

C4 Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-14T12:05:59.000Z - 6 months ago

C4 Therapeutics outlines milestones through 2028

Jan 14, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

2025-12-17T10:55:09.000Z - 7 months ago

C4 Therapeutics price target lowered to $5 from $10 at Barclays

Dec 3, 2025, 3:25 PM EST - 8 months ago

C4 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-12-02T10:40:12.000Z - 8 months ago

C4 Therapeutics initiated with a Buy at TD Cowen

Nov 25, 2025, 7:00 AM EST - 8 months ago

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

2025-11-21T21:10:22.000Z - 8 months ago

C4 Therapeutics files $400M mixed securities shelf

Nov 21, 2025, 7:00 AM EST - 8 months ago

C4 Therapeutics Registration statement: Registration Filing

Nov 12, 2025, 8:30 AM EST - 9 months ago

C4 Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-06T12:24:51.000Z - 9 months ago

C4 Therapeutics reports Q3 EPS (44c), consensus (38c)

2025-11-06T12:24:45.000Z - 9 months ago

C4 Therapeutics sees cash runway to the end of 2028

Nov 6, 2025, 7:00 AM EST - 9 months ago

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:00 AM EST - 9 months ago

C4 Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

C4 Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 6:00 PM EST - 9 months ago

C4 Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 9 months ago

C4 Therapeutics Slides: Corporate Presentation

2025-10-16T11:20:33.000Z - 10 months ago

C4 Therapeutics prices $125M underwritten offering

Oct 16, 2025, 7:08 AM EDT - 10 months ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

2025-10-01T11:10:58.000Z - 10 months ago

C4 Therapeutics announces trial collab, supply agreement with Pfizer

PFE

$C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma$

Oct 1, 2025, 7:00 AM EDT - 10 months ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

2025-09-23T10:15:16.000Z - 10 months ago

C4 Therapeutics price target raised to $10 from $5 at Wells Fargo

2025-09-22T11:15:14.000Z - 10 months ago

C4 Therapeutics price target raised to $10 from $8 at Barclays

2025-09-21T14:55:14.000Z - 10 months ago

C4 Therapeutics presents data from Phase 1 trial of cemsidomide

Sep 20, 2025, 3:00 PM EDT - 11 months ago

C4 Therapeutics Transcript: Status Update

Sep 20, 2025, 3:00 PM EDT - 11 months ago

C4 Therapeutics Slides: Status Update

Sep 20, 2025, 11:00 AM EDT - 11 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Sep 4, 2025, 7:00 AM EDT - 11 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 3, 2025, 7:00 AM EDT - 11 months ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Aug 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q2 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Slides: Corporate Presentation

Apr 29, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing

Mar 3, 2025, 9:10 AM EST - 1 year ago

C4 Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Annual report: Q4 2024

Feb 26, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Slides: Corporate Presentation

Feb 24, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Jan 15, 2025, 5:15 PM EST - 1 year ago

C4 Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

C4 Therapeutics Slides: FY 2025

Dec 8, 2024, 5:00 PM EST - 1 year ago

C4 Therapeutics Transcript: Status Update

Dec 8, 2024, 5:00 PM EST - 1 year ago

C4 Therapeutics Slides: Status Update

Dec 8, 2024, 12:30 PM EST - 1 year ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Nov 20, 2024, 3:00 AM EST - 1 year ago

C4 Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Registration statement: Registration Filing

Oct 31, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Registration statement: Registration Filing

Oct 31, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q3 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q3 2024

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Sep 18, 2024, 8:35 AM EDT - 2 years ago

C4 Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 13, 2024, 12:00 PM EDT - 2 years ago

C4 Therapeutics Transcript: Study Update

Sep 13, 2024, 12:00 PM EDT - 2 years ago

C4 Therapeutics Press release: Study Update

Sep 13, 2024, 12:00 PM EDT - 2 years ago

C4 Therapeutics Slides: Study Update

Sep 13, 2024, 10:00 AM EDT - 2 years ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 2 years ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 5, 2024, 8:45 AM EDT - 2 years ago

C4 Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 3, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Aug 29, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 1, 2024, 7:04 AM EDT - 2 years ago

C4 Therapeutics Quarterly report: Q2 2024

Aug 1, 2024, 7:04 AM EDT - 2 years ago

C4 Therapeutics Earnings release: Q2 2024

Aug 1, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 16, 2024, 4:01 PM EDT - 2 years ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 15, 2024, 12:00 PM EDT - 2 years ago

C4 Therapeutics Transcript: UBS Targeted Protein Degradation Day 2024

Jul 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jun 10, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Earnings release: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Slides: Corporate Presentation

Apr 29, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Proxy statement: Proxy Filing

Apr 16, 2024, 10:30 AM EDT - 2 years ago

C4 Therapeutics Transcript: Stifel Virtual Targeted Oncology Days Conference

Apr 9, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 8, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Earnings release: Q4 2023

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Annual report: Q4 2023

Jan 11, 2024, 12:00 PM EST - 2 years ago

C4 Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 11, 2024, 12:00 PM EST - 2 years ago

C4 Therapeutics Slides: FY 2024

Jan 11, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Slides: Corporate Presentation

Jan 9, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 4, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 12, 2023, 4:30 PM EST - 2 years ago

C4 Therapeutics Transcript: Study Update

$C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma$

Dec 12, 2023, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

$C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma$

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 1, 2023, 8:00 AM EDT - 2 years ago

C4 Therapeutics Quarterly report: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

C4 Therapeutics Earnings release: Q3 2023

Nov 1, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Oct 11, 2023, 7:00 AM EDT - 3 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

zawojak Jul. 24 at 6:18 AM

$CCCC my bios actually nog doing bad in this bear market. I have biggest loss with military stocks :/

0 · Reply

Andysss Jul. 23 at 1:12 PM

$CCCC well said. We are in for toxic combo. 10y flashing red. @LabPsycho are still holding ?

1 · Reply

JuggernautRaider Jul. 23 at 1:32 AM

$MIST thinking of loading up like I did $NUVB and $IMRX and $CCCC at $1.50 🧐

0 · Reply

JuggernautRaider Jul. 22 at 4:12 PM

$TNXP buying opportunities 😋 $IMRX $CCCC $PFE all on my Uncle Dave’s shopping list 📕 😋 💊

0 · Reply

JuggernautRaider Jul. 21 at 8:39 PM

Eat me like a sweet Italian sausage you Jabbroni. Stop whining - I don’t speak Why-Knees. Do your own due diligence or be quiet you baby $NUVB $CCCC $IMRX and $SLS all winners 🏆 🏆 🏆 🏆

1 · Reply

Jh900 Jul. 21 at 3:43 PM

0 · Reply

JuggernautRaider Jul. 21 at 10:15 AM

$CCCC this is a 4 diamond stock 💎 👊 what is the one thing it is missing? 👍

0 · Reply

JuggernautRaider Jul. 20 at 7:00 PM

$MAT gonna be a buyer 😋 soon. $TNXP $IMRX $CCCC … soon

0 · Reply

zawojak Jul. 20 at 3:46 PM

$CCCC Looks like no buyers for small cap stocks 😬 currently .

1 · Reply

buylocellhi Jul. 20 at 3:23 PM

$CCCC this is the 3rd time we have touched the $3.40-3.50 price point. Let’s hope this is the 3rd and last time so we can start moving up 📈

0 · Reply

zawojak Jul. 20 at 10:11 AM

$CCCC Is that the great market correction we are experiencing? My portfolio is pretty 🔻😬📉

0 · Reply

JuggernautRaider Jul. 20 at 1:33 AM

$TNXP $IMRX $CCCC $ALT 💎 💎 💎 💎

1 · Reply

buylocellhi Jul. 17 at 4:58 PM

$CCCC when this jumps over $4, you will see a s$&@t ton of buying which will then send it to $4.25! 🤩

0 · Reply

open_outcry Jul. 17 at 2:45 PM

$ACRV seems like nearly everyone on this board is trading this stock from a technical standpoint... i'm invested in this one on substance. it's a LOOOONG hold that will be a 10-bagger (or better). seems like the most obvious and lucrative play with this ticker, given it doesn't swing like some other bios ($CCCC)

2 · Reply

Andysss Jul. 17 at 1:56 PM

$CCCC if the 10Y continues to drop. Sig up today

1 · Reply

zawojak Jul. 16 at 2:40 PM

$CCCC added 150

0 · Reply

Jonita Jul. 16 at 2:11 PM

$CCCC in in in

0 · Reply

zawojak Jul. 16 at 1:11 PM

$CCCC $NUVB $UNCY $AQST $NLST Who still believes we are NOT in a BEAR market? 😬😬😬📉📉📉🔻🔻🔻

1 · Reply

Bullsarmy Jul. 15 at 11:21 PM

$CCCC Adding huge here

1 · Reply

zawojak Jul. 15 at 4:16 PM

$CCCC a whole US markets down on the on going war with Iran ...:(

0 · Reply

Andysss Jul. 15 at 1:50 PM

$CCCC insane manipulation of XBI

0 · Reply

Andysss Jul. 14 at 2:45 PM

$CCCC cooling CPI and XBI in red. Confused/algo manipulation.

0 · Reply

Market Cap	375.93M
Revenue (ttm)	35.95M
Net Income (ttm)	-104.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-292.04%
Debt to Equity Ratio	0.00

Volume	2,584,000
Avg Vol	3,400,902
Day's Range	N/A - N/A
Shares Out	110.57M
Stochastic %K	2%
Beta	2.90
Analysts	Strong Sell
Price Target	$13.33